Newly approved once-daily formulations of medications for the treatment of Attention Deficit (Hyperactivity) Disorder (ADHD) in children and adolescents.
Roman
Marian W
MW
University of Tennessee, College of Nursing, Knoxville, Tennessee 37996, USA. mroman@utk.edu
D000279:Administration, Cutaneous; D000293:Adolescent; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D002648:Child; D003692:Delayed-Action Preparations; D003913:Dextroamphetamine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D016316:Guanfacine / Q000008:administration & dosage; D006801:Humans; D000069478:Lisdexamfetamine Dimesylate; D008125:Locus Coeruleus / Q000187:drug effects; D008774:Methylphenidate / Q000008:administration & dosage; D009474:Neurons / Q000187:drug effects; D009749:Nutrition Surveys; D017397:Prefrontal Cortex / Q000187:drug effects; D011437:Propylamines / Q000008:administration & dosage
D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D011437:Propylamines; D008774:Methylphenidate; D016316:Guanfacine; D000069445:Atomoxetine Hydrochloride; D000069478:Lisdexamfetamine Dimesylate; D003913:Dextroamphetamine